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Summary of findings {#CD000526-sec1-0001}
===================

Summary of findings for the main comparisonCorticosteroids for tuberculous pericarditis in HIV‐negative people**Population:** HIV‐negative people with tuberculous pericarditis **Settings:** any setting **Intervention:** corticosteroids\
**Comaprison:** placebo**OutcomesIllustrative comparative risks (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsPlaceboSteroids**Death from all causes22 per 10018 per 100 (13 to 24)RR 0.80 (0.59 to 1.09)660 (4 trials)⊕⊕⊝⊝ low^1,2^Steroids may reduce the risk of deaths from all causes among HIV‐negative people.Death from pericarditis8 per 1003 per 100 (1 to 6)RR 0.39 (0.19 to 0.80)660 (4 trials)⊕⊕⊕⊝ moderate^2^Steroids probably reduce the risk of deaths from pericarditis among HIV‐negative people.Constrictive pericarditis10 per 1007 per 100 (3 to 15)RR 0.72 (0.34 to 1.55)281 (2 trials)⊕⊝⊝⊝ very low^2,3,4^It is uncertain whether steroids have an effect on the risk of constriction among HIV‐negative people.Repeat pericardiocentesis40 per 10034 per 100 (28 to 41)RR 0.85 (0.70 to 1.04)492 (2 trials)⊕⊕⊝⊝ low^1,4^Steroids may reduce the risk of repeat drainage of the pericardium among HIV‐negative people.Cancer1 per 1001 per 100 (0 to 12)RR 0.85 (0.05 to 13.80)256 (1 trial)⊕⊝⊝⊝ very low^3,5^It is uncertain whether steroids have an effect on the risk of cancer among HIV‐negative people.**Abbreviations:** CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^2]

Summary of findings 2Corticosteroids for tuberculous pericarditis in HIV‐positive people**Population:** HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs **Settings:** any setting **Intervention:** corticosteroids\
**Comparison:** placebo**OutcomesIllustrative comparative risks (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsPlaceboCorticosteroids**Death from all causes17 per 10015 per 100 (6 to 40)RR 0.91 (0.34 to 2.42)575 (3 trials)⊕⊝⊝⊝ very low^1,2^It is uncertain whether steroids have an effect on the risk of deaths from all causes among people living with HIV.Death from pericarditis4 per 1004 per 100 (2 to 10)RR 1.07 (0.46 to 2.54)517 (2 trials)⊕⊝⊝⊝ very low^1,3^It is uncertain whether steroids have an effect on the risk of deaths from pericarditis among people living with HIV.Constrictive pericarditis6 per 1004 per 100 (2 to 7)RR 0.55 (0.26 to 1.16)575 (3 trials)⊕⊕⊝⊝ low^1^Steroids may reduce the risk of developing constriction among people living with HIV.Repeat pericardiocentesis60 per 10061 per 100 (53 to 71)RR 1.02 (0.89 to 1.18)517 (2 trials)⊕⊕⊝⊝ low^3,5^Steroids may have little or no effect on the risk of repeat pericardiocentesis among people living with HIV.Cancer1 per 1001 per 100 (0 to 8)RR 1.62 (0.27 to 9.77)502 (1 trial)⊕⊝⊝⊝ very low^1,3^It is uncertain whether steroids have an effect on the risk of cancer among people living with HIV.**Abbreviations:** CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^3]

Background {#CD000526-sec1-0002}
==========

Description of the condition {#CD000526-sec2-0001}
----------------------------

Tuberculous pericarditis refers to an infection of the membrane that covers the heart (pericardium) by the bacterium *Mycobacterium tuberculosis.* Infection of the pericardium can result in fluid accumulation around the heart, which constrains the heart\'s pumping action (tamponade), and is life‐threatening. Sometimes the infection causes a thickening of the pericardium without an effusion (constrictive pericarditis), and this can also constrain the pumping action ([@CD000526-bbs2-0037]; [@CD000526-bbs2-0044]). Tuberculous pericarditis manifests with fatigue, shortness of breath, swelling of the body, and can cause death.

Healthcare practitioners in low‐ and middle‐income countries, where tuberculosis is common, are familiar with the condition ([@CD000526-bbs2-0024]; [@CD000526-bbs2-0059]). In high‐income countries, the condition occurs in less than 5% of all people with tuberculosis ([@CD000526-bbs2-0034]; [@CD000526-bbs2-0029]). The human immunodeficiency virus (HIV) epidemic has resulted in more cases of tuberculosis in Africa and other resource‐constrained regions, with a consequent rise in tuberculous pericarditis ([@CD000526-bbs2-0015]; [@CD000526-bbs2-0038]; [@CD000526-bbs2-0039]). Post‐mortem examinations conducted before the HIV era indicate that the pericardium is involved in 1% of people infected with tuberculosis ([@CD000526-bbs2-0020]). However, identical studies in people who died with advanced HIV reveal that extrapulmonary disease with multiple organ involvement is more frequent ([@CD000526-bbs2-0035]; [@CD000526-bbs2-0050]). In people living with HIV who have pericardial effusion, tuberculosis is the cause in over four‐fifths of cases ([@CD000526-bbs2-0042]). In addition, the burden of tuberculous pericarditis experienced a rapid increase in regions of the world where tuberculosis‐HIV co‐infection is common ([@CD000526-bbs2-0045]). This could be explained in part by the fact that the lifetime risk of tuberculosis in immune‐competent people without HIV infection is 10% ([@CD000526-bbs2-0032]), which increases to a yearly risk of 10% early in HIV infection and up to a 30% yearly risk in people with advanced immunosuppression ([@CD000526-bbs2-0036]).

In the pre‐antibiotic era, mortality of people with tuberculous pericarditis was 80% to 90% ([@CD000526-bbs2-0027]), but the advent of effective antituberculous chemotherapy in the 1940s resulted in a decrease in case fatality rate to about 35% by 1970 ([@CD000526-bbs2-0052]). However, even with antituberculous drug regimens that contain rifampicin and isoniazid, the mortality rate remains high and is estimated to be between 8% and 17% in people without HIV infection ([@CD000526-bbs2-0018]; [@CD000526-bbs2-0014]). In addition, HIV infection has an adverse effect on mortality rate ([@CD000526-bbs2-0037]; [@CD000526-bbs2-0043]; [@CD000526-bbs2-0008]). In one study, 185 participants with tuberculous pericarditis were consecutively enrolled in 15 referral hospitals in three African countries (Cameroon, Nigeria, and South Africa) between March 2004 and October 2004; and followed up during the six‐month course of antituberculous treatment ([@CD000526-bbs2-0038]). The mortality rate in this study was 17% in people without clinical evidence of HIV infection and 40% in people with clinical features of HIV infection ([@CD000526-bbs2-0039]). HIV‐associated tuberculous pericarditis more often occurs as part of a disseminated process with a greater amount of heart muscle involvement, and patients have larger fluid accumulation in the pericardium ([@CD000526-bbs2-0045]).

Description of the intervention {#CD000526-sec2-0002}
-------------------------------

Doctors currently prescribe rifampicin, isoniazid, pyrazinamide, and ethambutol for six months; remove fluid from the pericardium if the patient is very sick; and remove the membrane if it is thick and making the patient ill ([@CD000526-bbs2-0065]). However, the number of complications and deaths due to the disease remain high ([@CD000526-bbs2-0039]; [@CD000526-bbs2-0045]). It has been proposed that adding corticosteroids to antituberculous antibiotics would lead to further decreases in the aggressiveness of the disease and deaths. Some study authors recommend the routine use of corticosteroids in all cases of tuberculous pericarditis ([@CD000526-bbs2-0011]; [@CD000526-bbs2-0056]; [@CD000526-bbs2-0060]). In contrast, other experts advise that corticosteroids should be reserved for people who are critically ill with recurrent large effusion and who do not respond to pericardial drainage and antituberculous drugs alone ([@CD000526-bbs2-0034]).

In addition to the corticosteroid controversy, there is no consensus regarding the optimal use of other therapeutic interventions ([@CD000526-bbs2-0045]). Removal of fluid can be percutaneous under local anaesthesia or surgical under general anaesthesia. Furthermore, doctors can differ in the way they manage this condition in terms of duration of antituberculous drugs and when to operate. Other potential treatments for tuberculous pericarditis may include intrapericardial fibrinolysis ([@CD000526-bbs2-0012]), cellular therapy, use of repurposed drugs, cytokine therapy ([@CD000526-bbs2-0063]), and surgical removal of the thickened membrane (that is pericardiectomy) ([@CD000526-bbs2-0055]; [@CD000526-bbs2-0049]).

How the intervention might work {#CD000526-sec2-0003}
-------------------------------

### Length of treatment {#CD000526-sec3-0001}

Various specialists recommend different antibiotic treatment regimens of different lengths, from six months to 12 months ([@CD000526-bbs2-0053]; [@CD000526-bbs2-0020]; [@CD000526-bbs2-0031]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). It is uncertain whether longer treatment leads to better outcomes ([@CD000526-bbs2-0065]).

### Corticosteroids {#CD000526-sec3-0002}

The inflammatory response to tuberculous bacilli penetrating the pericardium is responsible for the morbidity and mortality associated with tuberculous pericarditis ([@CD000526-bbs2-0037]). Corticosteroids are anti‐inflammatory drugs that may attenuate the inflammatory response and improve outcomes by reducing the accumulation of fluid or development of adhesions in the pericardium ([@CD000526-bbs2-0008]). In people living with HIV, active tuberculosis increases immune activation and accelerates progression to the acquired immunodeficiency syndrome; which results in early death. Corticosteroids may improve survival in HIV‐positive people that have tuberculous pericarditis by modulating this immunological response ([@CD000526-bbs2-0008]). However, there is concern that corticosteroids may increase the risk of opportunistic infections and cancer in people living with HIV ([@CD000526-bbs2-0003]).

### Immunomodulators {#CD000526-sec3-0003}

As a result of advancements in the understanding of the immunopathogenesis of tuberculosis, there has been an increasing interest in immunotherapies as adjunctive treatments to standard antituberculous drug regimens. *Mycobacterium indicus pranii* is a non‐pathogenic, saprophytic, rapidly growing atypical *Mycobacterium* species that has immunomodulating properties ([@CD000526-bbs2-0054]). When administered as an intradermal heat‐killed vaccine, *M. indicus pranii* stimulates a Th1 cellular immune response against shared epitopes for *M. tuberculosis*, which leads to an improved cell‐mediated immune response, and therefore less severe disease ([@CD000526-bbs2-0023]; [@CD000526-bbs2-0058]). A systematic review suggested that *M. indicus pranii* administration may reduce the time to cure of pulmonary tuberculosis, while acknowledging the need for further large trials ([@CD000526-bbs2-0046]).

### Surgical options {#CD000526-sec3-0004}

#### Early drainage {#CD000526-sec4-0001}

Complete drainage of the pericardial fluid is sometimes performed as an open surgical procedure under general anaesthesia ([@CD000526-bbs2-0007]), or percutaneously under local anaesthesia with ultrasound or fluoroscopic guidance. The requirement and optimal method for drainage is not known ([@CD000526-bbs2-0007]).

#### Removal of the pericardium {#CD000526-sec4-0002}

In tuberculous constrictive pericarditis, some specialists advise an early conservative approach with surgery applied to patients who do not respond after an initial period of antituberculous medication ([@CD000526-bbs2-0055]). Others advise early surgery in all affected cases ([@CD000526-bbs2-0049]).

Why it is important to do this review {#CD000526-sec2-0004}
-------------------------------------

This is an update of a Cochrane Review first published in 2000 ([@CD000526-bbs2-0064]), and previously updated in 2002 ([@CD000526-bbs2-0065]). The previous version included four trials of corticosteroids ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). Early publications of small trials conducted in the pre‐HIV era reported fewer deaths with corticosteroids compared to placebo, but the confidence interval (CI) ranged from a substantial reduction to a clinically important increase in deaths (risk ratio 0.65, 95% CI 0.36 to 1.16; 350 participants, 2 trials) ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). Similar results were obtained among people living with HIV (risk ratio 0.50, 95% CI 0.19 to 1.28; 58 participants, 1 trial) ([@CD000526-bbs2-0001]). One trial showed that complete drainage of the pericardial fluid may relieve cardiac tamponade ([@CD000526-bbs2-0007]). However, two previously included trials have reported additional data ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]), and various potentially eligible trials have been published since 2002 ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0009]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]; [@CD000526-bbs2-0002]).

Objectives {#CD000526-sec1-0003}
==========

To assess the effects of treatments for tuberculous pericarditis.

Methods {#CD000526-sec1-0004}
=======

Criteria for considering studies for this review {#CD000526-sec2-0005}
------------------------------------------------

### Types of studies {#CD000526-sec3-0005}

Randomized controlled trials (RCTs) and quasi‐RCTs.

### Types of participants {#CD000526-sec3-0006}

People of all ages that required treatment for clinically diagnosed tuberculous pericarditis (effusive, constrictive, or effusive‐constrictive), whether HIV‐negative or HIV‐positive.

### Types of interventions {#CD000526-sec3-0007}

Long versus shorter durations of antituberculous chemotherapy.Corticosteroids versus no corticosteroids.Immunomodulators versus no immunomodulators.Surgical procedures versus conservative management.Other treatments for tuberculous pericarditis.

### Types of outcome measures {#CD000526-sec3-0008}

#### Primary outcomes {#CD000526-sec4-0003}

Deaths from all causes.

#### Secondary outcomes {#CD000526-sec4-0004}

Death from pericarditis.Constrictive pericarditis.Repeat pericardiocentesis.Cancer.Hospitalization.Pericardiectomy.Opportunistic infections.

Search methods for identification of studies {#CD000526-sec2-0006}
--------------------------------------------

### Electronic searches {#CD000526-sec3-0009}

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

We searched the following databases using the strategy described in [Appendix 1](#CD000526-sec2-0016){ref-type="app"}: the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017).

### Searching other resources {#CD000526-sec3-0010}

We searched the metaRegister of Controlled Trials (mRCT) and the WHO International Clinical Trials Registry Platform (ICTRP) search portal using \'tuberculosis\' and \'pericard\*\' as search terms on 27 March 2017.

We also searched ClinicalTrials.gov and contacted researchers in the field of tuberculous pericarditis in March 2017.

In addition, we examined existing reviews of tuberculous pericarditis for relevant citations ([@CD000526-bbs2-0055]; [@CD000526-bbs2-0014]; [@CD000526-bbs2-0020]; [@CD000526-bbs2-0021]; [@CD000526-bbs2-0011]; [@CD000526-bbs2-0056]; [@CD000526-bbs2-0022]; [@CD000526-bbs2-0016]; [@CD000526-bbs2-0019]; [@CD000526-bbs2-0060]; [@CD000526-bbs2-0065]; [@CD000526-bbs2-0041]; [@CD000526-bbs2-0037]; [@CD000526-bbs2-0061]; [@CD000526-bbs2-0029]; [@CD000526-bbs2-0063]).

Data collection and analysis {#CD000526-sec2-0007}
----------------------------

We conducted screening of search outputs, assessment of potentially eligible studies, assessment of risk of bias, and data extraction for this review in line with the Cochrane policy on trial authors who are also review authors ([@CD000526-bbs2-0030]). In addition, two Cochrane Infectious Disease Group (CIDG) Editors (Paul Garner and David Sinclair) provided oversight for data collection and analysis.

### Selection of studies {#CD000526-sec3-0011}

Three review authors, Charles Wiysonge (CSW), Dumo Majombozi (DM), and Bongani M Mayosi (BMM), independently screened abstracts identified by the search strategy for potentially eligible studies. The three review authors obtained the full‐text articles of any potentially relevant articles and then assessed these studies using the prespecified trial inclusion criteria, respecting the Cochrane policy on trial authors who are also review authors ([@CD000526-bbs2-0030]). We resolved any disagreements by discussion and consensus.

Six review authors, Mpiko Ntsekhe (MN), Lehana Thabane (LT), Jimmy Volmink (JV), Freedom Gumedze (FG), Shaheen Pandie (SP), and BMM, were involved in one trial that met the inclusion criteria of this review ([@CD000526-bbs2-0003]). Two review authors who were not involved with this trial, namely CSW and DM, independently performed the application of the inclusion criteria, \'Risk of bias\' assessments, and data extraction for this trial. We excluded one potentially eligible study that did not meet the inclusion criteria and documented the reason for exclusion in the \'[Characteristics of excluded studies](#CD000526-sec2-0020){ref-type="sec"}\' table. Four review authors, CSW, MN, FG, JV, and BMM, are the authors of an excluded study ([@CD000526-bbs2-0008]). In order to conform to existing Cochrane policies ([@CD000526-bbs2-0028]; [@CD000526-bbs2-0030]), a review author who was not involved in this study (DM) made the initial assessment of the eligibility of this study. We have included a study that is awaiting assessment in the \'[Characteristics of studies awaiting classification](#CD000526-sec2-0021){ref-type="sec"}\' table ([@CD000526-bbs2-0009]).

### Data extraction and management {#CD000526-sec3-0012}

Two review authors (either CSW and BMM, or CSW and DM) independently extracted information from the included trials on methods used, participant characteristics, interventions, and outcomes. For all outcomes, we extracted the number of participants randomized and the number of participants analysed. The trials identified and included in this review all randomized individual participants and reported dichotomous outcomes. For each trial, we extracted the number of participants randomized to each intervention, as well as the number of participants with an outcome of interest and the number included in the analysis by the trial authors.

The published article from the [@CD000526-bbs2-0003] trial did not provide data by HIV status, but we requested and obtained these data from the study statistician (FG). CSW entered the data into Review Manager (RevMan) ([@CD000526-bbs2-0051]), and the study statistician FG verified the entered data for accuracy.

Multiple publications from the same data constituted one included trial, and we marked the publication that provided the most data to the analyses as the primary reference ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]). If data were available on prespecified outcomes at two or more periods, we took the more complete or later one into account ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]).

### Assessment of risk of bias in included studies {#CD000526-sec3-0013}

One review author (CSW) assessed the risk of bias in each included trial using Cochrane\'s \'Risk of bias\' assessment tool for assessing the risk of bias in intervention studies ([@CD000526-bbs2-0028]), and two review authors (BMM and DM) verified this assessment; in line with the Cochrane policy on trial authors who are also review authors ([@CD000526-bbs2-0030]). We assessed whether adequate steps were taken to reduce the risk of bias across seven specific domains, namely, random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; completeness of outcome data; selective outcome reporting; and other issues. For each included trial, we described what the trial authors reported that they did for each domain and decided the risk of bias for that domain by assigning a judgement of \'low\', \'high\', or \'unclear risk\' of bias.

We categorized each included study into one of two levels of bias: low or high risk of bias. Studies with a high risk of selection bias (from inadequate random sequence generation and/or allocation concealment), detection bias (from lack of blinding of outcome assessment), or attrition bias (from incomplete outcome data) were categorized as having high risk of bias. We considered all other included trials to have a low risk of bias. We compared the results of independent \'Risk of bias\' assessments and resolved disagreements by consensus.

### Measures of treatment effect {#CD000526-sec3-0014}

All of the included trials reported dichotomous data, so we expressed the results as risk ratios (RR) with 95% CIs for each outcome.

### Unit of analysis issues {#CD000526-sec3-0015}

We did not encounter any unit of analysis issues in this review, as all included trials were individually RCTs.

### Dealing with missing data {#CD000526-sec3-0016}

We stratified analyses by HIV status. However, data on HIV status were unavailable in three trials that were conducted (or started recruitment) in South Africa before the onset of the HIV epidemic in the country. We have assumed that the participants in these studies did not have HIV infection ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). One trial only enrolled HIV‐positive people ([@CD000526-bbs2-0001]), and two recruited both HIV‐positive and HIV‐negative people ([@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]). The published paper from one of the two trials did not disaggregate results by HIV status ([@CD000526-bbs2-0003]). We requested and obtained the disaggregated outcome data from the trial statistician (FG).

### Assessment of heterogeneity {#CD000526-sec3-0017}

We assessed whether there was heterogeneity of study participants, interventions, and outcomes in order to make a qualitative assessment of the extent to which the included studies were similar to each other. We then included clinically homogeneous studies in meta‐analyses and assessed heterogeneity of study results by visually inspecting the forest plots to check for overlapping CIs. In addition, we assessed heterogeneity of effects using the Chi² test of homogeneity; with statistical significance defined at the 10% alpha level (that is, P = 0.10). We also used the I² statistic to quantify the proportion of observed variation of effects across studies, which reflected variation in true effect sizes rather than sampling error ([@CD000526-bbs2-0028]).

### Assessment of reporting biases {#CD000526-sec3-0018}

There were too few included studies to examine publication bias using a funnel plot ([@CD000526-bbs2-0028]).

### Data synthesis {#CD000526-sec3-0019}

Using both unpublished ([@CD000526-bbs2-0003]), and published data ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]), we analysed trial participants in groups to which they were randomized; regardless of how much of the intended intervention they actually received. One included study used a 2 x 2 factorial design, in which participants received prednisolone plus *M. indicus pranii*, prednisolone plus placebo, *M. indicus pranii* plus placebo, or double placebo. There was a suggestion of clinical interaction between prednisolone and *M. indicus pranii* on cancer incidence ([@CD000526-bbs2-0003]). Ten of the 14 cases of cancer (71.4%) occurred in the group that took prednisolone plus *M. indicus pranii.* Therefore, in the analysis of intervention effects, we considered data from the group that took only one active intervention (that is, prednisolone or *M. indicus pranii*, as the case may be); and excluded data from the group that received both interventions.

We used meta‐analysis with a fixed‐effect model to calculate the summary statistics. We stratified analyses according to HIV status and the type of treatment and control intervention, for example, adjunctive corticosteroids versus placebo or no treatment in HIV‐negative people, adjunctive corticosteroids versus placebo or no treatment in people living with HIV.

In addition, we used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to assess the certainty of the evidence for each outcome ([@CD000526-bbs2-0026]). We have summarized the certainty of the evidence for corticosteroids in the \'Summary of findings\' tables ([Table 1](#CD000526-tbl-0001){ref-type="table"}; [Table 2](#CD000526-tbl-0002){ref-type="table"}), which we constructed using GRADEpro Guideline Development Tool software ([@CD000526-bbs2-0025]).

### Subgroup analysis and investigation of heterogeneity {#CD000526-sec3-0020}

We only conducted meta‐analyses for studies with homogeneous participants, interventions, and outcomes. If we had at least 10 studies in any meta‐analysis that showed significant statistical heterogeneity (that is, P \< 0.10), we would have explored possible sources of heterogeneity by performing subgroup analyses; with subgroups defined by clinical syndromes of tuberculous pericarditis (that is, pericardial effusion versus constriction) and risk of bias (that is, low versus high).

Results {#CD000526-sec1-0005}
=======

Description of studies {#CD000526-sec2-0008}
----------------------

### Results of the search {#CD000526-sec3-0021}

We have presented a PRISMA diagram that illustrates the study selection process in [Figure 1](#CD000526-fig-0001){ref-type="fig"}.Figure 1Study flow diagram

For this Cochrane Review update, we performed a literature search up to 27 March 2017 covering all years; including the years covered by the previous version of the review ([@CD000526-bbs2-0065]). This literature search yielded 17 publications. We judged four of the publications to be clearly irrelevant to the review and excluded them. We obtained the full‐text articles of the 13 potentially eligible publications and assessed them for eligibility. Four articles, which contain data from four distinct studies ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]), were already included in the previous published version of the review ([@CD000526-bbs2-0065]). We excluded one article due to ineligible study design ([@CD000526-bbs2-0008]), and another one is awaiting assessment ([@CD000526-bbs2-0009]). One study has not yet published outcome data and we classified it as ongoing ([@CD000526-bbs2-0010]). The remaining six publications, which contain data from six distinct studies, met our inclusion criteria ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]; [@CD000526-bbs2-0002]). The most recent follow‐up data for two included trials were published as one article ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]).

### Included studies {#CD000526-sec3-0022}

The seven eligible trials consisted of six single‐country studies conducted in South Africa ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]) and Zimbabwe ([@CD000526-bbs2-0001]), as well as a multicountry study conducted in Kenya, Malawi, Mozambique, Nigeria, Sierra Leone, South Africa, Uganda, and Zimbabwe ([@CD000526-bbs2-0003]). The interventions evaluated were as follows.

Corticosteroids ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]).Colchicine ([@CD000526-bbs2-0002]).*M. indicus pranii* immunotherapy ([@CD000526-bbs2-0003]).Open surgical drainage on admission in participants with tuberculous pericardial effusion ([@CD000526-bbs2-0007]).

We have provided details of the included studies in the \'[Characteristics of included studies](#CD000526-sec2-0019){ref-type="sec"}\' tables.

#### Optimum duration of treatment {#CD000526-sec4-0005}

We did not find any eligible studies that assessed different durations of antituberculosis drug regimens .

#### Corticosteroids {#CD000526-sec4-0006}

We have provided key characteristics of the six included corticosteroid trials in [Table 9](#CD000526-tbl-0009){ref-type="table"}.Table 1Key characteristics of the corticosteroid trials**TrialLocationParticipantsInterventionOutcomesSample sizeAge (years)HIV‐positiveARTDefinite TB**[@CD000526-bbs2-0005]South Africa28 people with pericardial effusionAdultsNoneN/ANot reportedCortisone (or prednisolone) for several weeks versus no corticosteroids^1^Pericardiectomy[@CD000526-bbs2-0001]Zimbabwe58 people with pericardial effusion18 to 55100%0%38%Prednisolone for 6 weeks versus placebo^3^All‐cause deaths; constrictive pericarditis.[@CD000526-bbs2-0006]South Africa143 with constrictive pericarditis≥ 5Assume\
noneN/A10%Prednisolone first 11 weeks versus placebo^2^All‐cause deaths; deaths from pericarditis; pericardiectomy.[@CD000526-bbs2-0007]South Africa240 people with pericardial effusion≥ 5Assume\
noneN/A60%(1) Prednisolone for 11 weeks versus placebo\
(2) Open surgical drainage versus no drainageAll‐cause deaths; deaths from pericarditis; repeat pericardiocentesis; pericardiectomy.[@CD000526-bbs2-0004]South Africa40 people with pericardial effusion17 to 6638%0%Not reportedPrednisone versus no prednisone (5 mL intrapericardial 0.9% saline)^4^Repeat pericardiocentesis; pericardiectomy; constrictive pericarditis; infection.[@CD000526-bbs2-0003]Kenya, Malawi, Mozambique, Nigeria, Uganda, Sierra Leone, South Africa, and Zimbabwe1440 with pericardial effusion (83%) or constriction (17%)≥ 1867%22%17%Prednisolone for 6 weeks with or without *M. indicus pranii* versus placebo^5^All‐cause deaths; deaths from pericarditis; constrictive pericarditis; hospitalization; infection; cancer.[^4]

The six trials enrolled a total of 1926 participants. Over half of the participants (1018/1926; 52.9%) were confirmed HIV‐positive. Only one study gave antiretroviral drugs to participants, with 203 (22%) of these HIV‐positive participants on antiretroviral drugs, and thus overall only 19.9% of participants in the meta‐analysis on antiretroviral therapy at enrolment. Five trials enrolled people with pericardial effusion ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]), and one enrolled those with pericardial constriction ([@CD000526-bbs2-0006]).

The corticosteroids assessed were cortisone ([@CD000526-bbs2-0005]), prednisone and triamcinolone hexacetonide ([@CD000526-bbs2-0004]), and prednisolone ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]). [@CD000526-bbs2-0005] did not specify the length of follow‐up and [@CD000526-bbs2-0004] reported it as one year; [@CD000526-bbs2-0001] as 18 months; [@CD000526-bbs2-0003] as two years; and [@CD000526-bbs2-0006] and [@CD000526-bbs2-0007] as 10 years.

#### Colchicine {#CD000526-sec4-0007}

One trial tested the effects of colchicine among 33 people with a definite or probable diagnosis of tuberculous pericarditis in Kimberley, South Africa ([@CD000526-bbs2-0002]). All 33 participants were HIV‐positive and had pericardial effusion at enrolment. Participants in the intervention arm received colchicine 1.0 mg per day for six weeks. The control arm received identical placebo for six weeks as well. The length of follow‐up was 16 weeks ([@CD000526-bbs2-0002]).

#### *M. indicus pranii* immunotherapy {#CD000526-sec4-0008}

One trial evaluated the effects of an immunomodulator, *M. indicus pranii,* among 1250 people aged 18 years or older in sub‐Saharan Africa ([@CD000526-bbs2-0003]). Two thirds (840/1250; 67.2%) of the participants were confirmed to be HIV‐positive; with 172 (20.5%) on antiretroviral therapy at enrolment. All participants had pericardial effusion at enrolment. The *M. indicus pranii* preparation was given in five doses; at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The control arm received identical placebo following the same schedule, and the length of follow‐up was two years. This trial also assessed the effects of corticosteroids ([@CD000526-bbs2-0003]).

#### Surgical drainage {#CD000526-sec4-0009}

One trial assessed the effects of routine open surgical drainage on admission compared to no open surgical drainage in 122 participants with tuberculous pericardial effusion in Umtata, South Africa ([@CD000526-bbs2-0007]). This trial was conducted before the onset of the HIV epidemic in the country. This study reported data at two years and at 10 years of follow‐up. This trial also assessed the effects of corticosteroids ([@CD000526-bbs2-0007]).

#### Intrapericardial fibrinolysis {#CD000526-sec4-0010}

We found an ongoing trial that is assessing the effects of complete percutaneous pericardial drainage using intrapericardial alteplase compared to conventional pericardiocentesis in Cape Town, South Africa. The study started in 2016 and plans to recruit 2176 people with large pericardial effusion due to tuberculous and non‐tuberculous pericarditis. The trial started with a pilot phase involving 218 people. This will confirm the feasibility of conducting a large‐scale multicentre clinical trial of intrapericardial fibrinolysis in people with large pericardial effusions ([@CD000526-bbs2-0010]).

#### Other treatments {#CD000526-sec4-0011}

We did not find eligible studies that assessed other potential treatments for tuberculous pericarditis such as pericardiectomy, percutaneous drainage of the pericardium under local anaesthesia, cellular therapy, use of repurposed drugs, or cytokine therapy.

### Excluded studies {#CD000526-sec3-0023}

The excluded study is a cross‐sectional analysis of the contemporary use of adjunctive corticosteroids in the management of patients with tuberculous pericarditis in Africa ([@CD000526-bbs2-0008]). Despite being observational in nature, this study is indexed in electronic databases as a controlled trial. We have provided furthermore details on this study in the \'[Characteristics of excluded studies](#CD000526-sec2-0020){ref-type="sec"}\' table.

#### Studies awaiting assessment {#CD000526-sec4-0012}

One study is awaiting assessment, because the full‐text article is in Chinese and we do not yet have an English translation ([@CD000526-bbs2-0009]). In the study, consecutively recruited participants were \"randomly\" assigned to intervention or control arms, but the study authors did not provide any details about random sequence generation and allocation concealment in the study abstract. We have provided available details on this study in the \'[Characteristics of studies awaiting classification](#CD000526-sec2-0021){ref-type="sec"}\' table.

Risk of bias in included studies {#CD000526-sec2-0009}
--------------------------------

We have summarized our \'Risk of bias\' judgements for each included trial in [Figure 2](#CD000526-fig-0002){ref-type="fig"} and [Figure 3](#CD000526-fig-0003){ref-type="fig"}.Figure 2ʽRisk of bias\' graph: review authors\' judgements about each ʽRisk of bias\' item presented as percentages across all included studiesFigure 3ʽRisk of bias\' summary: review authors\' judgements about each ʽRisk of bias\' item for each included study

### Allocation {#CD000526-sec3-0024}

Five trials adequately generated the randomization sequence by either a computer ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0003]; [@CD000526-bbs2-0002]), or a random number list ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). The adequacy of the generation of the randomization sequence was unclear in one trial ([@CD000526-bbs2-0004]), and inadequate in the other trial ([@CD000526-bbs2-0005]). The concealment of allocation to treatment arms was adequate in five trials ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]; [@CD000526-bbs2-0002]), and inadequate in two trials ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0004]).

### Blinding {#CD000526-sec3-0025}

Participants, care providers, and outcome assessors were blinded to treatment allocation in four trials ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]). One study did not use blinding ([@CD000526-bbs2-0005]). One study reported that \"upon completion of the research period, the blinding was unveiled\", but does not provide details on how the blinding was done ([@CD000526-bbs2-0002]). In the sixth study there was blinding of participants and care providers, but it is unclear if outcome assessors were blind to treatment allocation ([@CD000526-bbs2-0004]).

### Incomplete outcome data {#CD000526-sec3-0026}

Loss to follow‐up was minimal (0% to 5%) and non‐differential in four included trials ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]). One trial did not adequately report losses to follow‐up ([@CD000526-bbs2-0005]), but losses to follow‐up were high (15% to 16%) in two trials ([@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]).

### Selective reporting {#CD000526-sec3-0027}

One trial was free of reporting bias as the planned outcomes (as indicated in the prospective trial registration \[ClinicalTrials.gov registration; NCT100810849\] and published protocol) were reported in the trial report ([@CD000526-bbs2-0003]). It was unclear to us if the remaining six studies ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]) were free from reporting bias; since none of the study protocols were available and none of the trials were prospectively registered.

### Other potential sources of bias {#CD000526-sec3-0028}

There is no evidence that the included studies had a high risk of other sources of bias; apart from those described above.

#### Overall \'Risk of bias\' assessment {#CD000526-sec4-0013}

Based on the results of the \'Risk of bias\' assessments for the seven domains above, we classified each included trial as either at low risk of bias or high risk of bias. Four trials had a low risk of bias ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]). The other three included trials were each at high risk of bias ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]).

Effects of interventions {#CD000526-sec2-0010}
------------------------

See: [Table 1](#CD000526-tbl-0001){ref-type="table"}; [Table 2](#CD000526-tbl-0002){ref-type="table"}

### 1. Corticosteroids versus no corticosteroids in HIV‐negative people {#CD000526-sec3-0029}

#### 1.1. Deaths from all causes {#CD000526-sec4-0014}

Four trials showed that corticosteroids may reduce deaths from all causes in HIV‐negative people ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]), but the 95% CI includes the possibility of both a large beneficial effect and a small increase in harm: risk ratio (RR) 0.80, 95% CI 0.59 to 1.09; 660 participants, 4 trials; [Analysis 1.1](#CD000526-fig-00101){ref-type="fig"}). We rated the certainty of the evidence as low ([Table 1](#CD000526-tbl-0001){ref-type="table"}).

#### 1.2. Deaths from pericarditis {#CD000526-sec4-0015}

Four trials provided data on deaths from pericarditis in people without HIV infection ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]). Pooling these data shows that corticosteroids probably reduce deaths from pericarditis: RR 0.39, 95% CI 0.19 to 0.80; 660 participants, 4 trials; [Analysis 1.2](#CD000526-fig-00102){ref-type="fig"}. We rated the certainty of the evidence as moderate ([Table 1](#CD000526-tbl-0001){ref-type="table"}).

#### 1.3. Constrictive pericarditis {#CD000526-sec4-0016}

Based on two included trials, [@CD000526-bbs2-0004] and [@CD000526-bbs2-0003], we are uncertain whether corticosteroids reduce the risk of constrictive pericarditis in people without HIV infection: RR 0.72, 95% CI 0.34 to 1.55; 281 participants, 2 trials; [Analysis 1.3](#CD000526-fig-00103){ref-type="fig"}). This evidence is of very low certainty ([Table 1](#CD000526-tbl-0001){ref-type="table"}).

#### 1.4. Repeat pericardiocentesis {#CD000526-sec4-0017}

Based on two included trials, [@CD000526-bbs2-0007] and [@CD000526-bbs2-0003], corticosteroids may reduce the reaccumulation of fluid requiring repeat drainage of the pericardium among HIV‐negative people, but the CIs include the possibility of both large beneficial effects and a small increase in harm: RR 0.85, 95% CI 0.70 to 1.04; 492 participants, 2 trials; [Analysis 1.4](#CD000526-fig-00104){ref-type="fig"}. We rated the certainty of the evidence as low ([Table 1](#CD000526-tbl-0001){ref-type="table"}).

#### 1.5. Cancer {#CD000526-sec4-0018}

From the limited data on cancer reported by one trial ([@CD000526-bbs2-0003]), we are uncertain about the effect of corticosteroids on the risk of cancer (RR 0.85, 95% CI 0.05 to 13.80; 256 participants ([Analysis 1.5](#CD000526-fig-00105){ref-type="fig"}) in HIV‐negative people, as the evidence is of very low certainty ([Table 1](#CD000526-tbl-0001){ref-type="table"}).

#### 1.6. Hospitalization {#CD000526-sec4-0019}

Only one trial reported on this outcome ([@CD000526-bbs2-0003]). We are uncertain whether corticosteroids reduce the risk of hospitalization in HIV‐negative people (RR 0.98, 95% CI 0.57 to 1.70; 256 participants, 1 trial; [Analysis 1.6](#CD000526-fig-00106){ref-type="fig"}), as the currently available evidence is of very low certainty. We downgraded the evidence by two for imprecision, as the CI ranges from clinically important benefits to a large increase in harm. In addition, we downgraded by one for selective reporting, given that data were only reported by one of four trials that recruited HIV‐negative people.

#### 1.7. Pericardiectomy {#CD000526-sec4-0020}

Based on data from four trials ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]), we are uncertain about the effects of corticosteroids on the risk of pericardiectomy in HIV‐negative people: RR 0.91, 95% CI 0.58 to 1.41; 432 participants, 4 trials; [Analysis 1.7](#CD000526-fig-00107){ref-type="fig"}). We rated the evidence to be of very low certainty. We downgraded the evidence by two for imprecision, as the CI ranges from large benefits to clinically important harms. We further downgraded by one for study limitations, given that two of the four trials were at high risk of bias.

#### 1.8. Opportunistic infections {#CD000526-sec4-0021}

We do not know whether corticosteroids have an effect on opportunistic infections as the certainty of the evidence was assessed as very low (RR 1.71, 95% CI 0.44 to 6.69; 256 participants, 1 trial; [Analysis 1.8](#CD000526-fig-00108){ref-type="fig"}). We downgraded the evidence by two for imprecision, as the CI ranges from clinically important benefits to a large increase in harm. In addition, we downgraded by one for selective reporting, given that data were only reported by one of four trials that recruited HIV‐negative people.

### 2. Corticosteroids versus no corticosteroids in people living with HIV infection {#CD000526-sec3-0030}

#### 2.1. Deaths from all causes {#CD000526-sec4-0022}

Three included trials reported on this outcome ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]). It is uncertain whether corticosteroids have an effect on the risk of deaths from any cause among people living with HIV (RR 0.91, 95% CI 0.34 to 2.42; 575 participants, 3 trials; [Analysis 2.1](#CD000526-fig-00201){ref-type="fig"}). This evidence is of very low certainty ([Table 2](#CD000526-tbl-0002){ref-type="table"}).

#### 2.2. Deaths from pericarditis {#CD000526-sec4-0023}

Two trials provided data on the effects of corticosteroids on deaths from pericarditis among 517 people living with HIV ([@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]). From these data, we are uncertain whether corticosteroids have an effect on the risk of deaths from pericarditis in HIV‐positive people (RR 1.07, 95% CI 0.46 to 2.54; 517 participants, 2 trials; [Analysis 2.2](#CD000526-fig-00202){ref-type="fig"}; *very low certainty evidence*; [Table 2](#CD000526-tbl-0002){ref-type="table"}).

#### 2.3. Constrictive pericarditis {#CD000526-sec4-0024}

Currently available data from three included trials ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]), show that corticosteroids may reduce the risk of constrictive pericarditis among people living with HIV, but the CIs include the possibility of both large beneficial effects and a small increase in harm (RR 0.55, 0.26 to 1.16; 575 participants, 3 trials; [Analysis 2.3](#CD000526-fig-00203){ref-type="fig"}; *low certainty evidence*; [Table 2](#CD000526-tbl-0002){ref-type="table"}).

#### 2.4. Repeat pericardiocentesis {#CD000526-sec4-0025}

Two trials reported data on the risk of reaccumulation of fluids requiring repeat drainage of the pericardium in HIV‐positive people ([@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]). The combined data show that corticosteroids may have little or no effect on this outcome (RR 1.02, 95% CI 0.89 to 1.18; 517 participants, 2 trials; [Analysis 2.4](#CD000526-fig-00204){ref-type="fig"}; *low certainty evidence*; [Table 2](#CD000526-tbl-0002){ref-type="table"}).

#### 2.5. Cancer {#CD000526-sec4-0026}

Based on currently available data from one included trial, [@CD000526-bbs2-0003], we are uncertain about the effects of corticosteroids on the risk of cancer in people living with HIV (RR 1.62, 95% CI 0.27 to 9.77; 502 participants, 1 trial; [Analysis 2.5](#CD000526-fig-00205){ref-type="fig"}; *very low certainty evidence*; [Table 2](#CD000526-tbl-0002){ref-type="table"}).

#### 2.6. Hospitalization {#CD000526-sec4-0027}

Based on one included trial, [@CD000526-bbs2-0003], corticosteroids may reduce the risk of hospitalization in people living with HIV, but the CIs include the possibility of both large beneficial effects and a small increase in harm (RR 0.80, 95% CI 0.59 to 1.09; 502 participants, 1 trial; [Analysis 2.6](#CD000526-fig-00206){ref-type="fig"}). This evidence is of low certainty. We downgraded the evidence by one for imprecision, as the CI ranges from clinically important benefits to little or no effect. In addition, we downgraded by one for selective reporting, given that data were only reported by one of three trials that recruited HIV‐negative people.

#### 2.7. Pericardiectomy {#CD000526-sec4-0028}

There is insufficient evidence from one included trial, [@CD000526-bbs2-0004], to determine whether corticosteroids have an effect on the risk of pericardiectomy in people living with HIV (RR 2.10, 95% CI 0.10 to 44.40; 15 participants, 1 trial; [Analysis 2.7](#CD000526-fig-00207){ref-type="fig"}; *very low certainty evidence*). We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for selective reporting, given that data were only reported by one of three trials that recruited HIV‐negative people.

#### 2.8. Opportunistic infections {#CD000526-sec4-0029}

Based on data from two included trials, [@CD000526-bbs2-0004] and [@CD000526-bbs2-0003], it is uncertain whether corticosteroids have an effect on the risk of opportunistic infections in HIV‐positive people (RR 0.95, 95% CI 0.61 to 1.48; 517 participants, 2 trials; [Analysis 2.8](#CD000526-fig-00208){ref-type="fig"}). We assessed the certainty of this evidence as very low. We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for study limitations, given that one of the two trials has a high risk of bias.

### 3. Colchicine versus placebo {#CD000526-sec3-0031}

From the results of one trial among 33 HIV‐positive people ([@CD000526-bbs2-0002]), it is uncertain whether colchicine has an effect on the risk of deaths from all causes (RR 0.74, 95% CI 0.17 to 3.12; [Analysis 3.1](#CD000526-fig-00301){ref-type="fig"}) or constrictive pericarditis (RR 1.11, 95% CI 0.21 to 5.76; [Analysis 3.2](#CD000526-fig-00302){ref-type="fig"}). We assessed the certainty of the evidence for each outcome as very low. We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for study limitations, given that the included trial has a high risk of bias.

### 4. *M. indicus pranii* versus placebo {#CD000526-sec3-0032}

One trial evaluated the effects of *M. indicus pranii* immunotherapy in a two‐by‐two factorial design among 1250 people aged 18 years or older in Zimbabwe, South Africa, Sierra Leone, Uganda, Nigeria, Mozambique, Malawi, and Kenya ([@CD000526-bbs2-0003]).

The trial reveals uncertainty about the effects of *M. indicus pranii* on deaths from all causes (RR 1.07, 95% CI 0.56 to 2.03; [Analysis 4.1](#CD000526-fig-00401){ref-type="fig"}), deaths from pericarditis (RR 1.50, 95% CI 0.44 to 5.15; [Analysis 4.2](#CD000526-fig-00402){ref-type="fig"}), constrictive pericarditis (RR 1.56, 95% CI 0.71 to 3.42; [Analysis 4.3](#CD000526-fig-00403){ref-type="fig"}), repeat pericardiocenthesis (RR 1.21, 95% CI 0.96 to 1.52; [Analysis 4.4](#CD000526-fig-00404){ref-type="fig"}), cancer (RR 3.03, 95% CI 0.12 to 75.37; [Analysis 4.5](#CD000526-fig-00405){ref-type="fig"}), hospitalization (RR 1.22, 95% CI 0.70 to 2.13; [Analysis 4.6](#CD000526-fig-00406){ref-type="fig"}), and opportunistic infections (RR 0.67, 95% CI from 0.11 to 3.90; [Analysis 4.7](#CD000526-fig-00407){ref-type="fig"}) in HIV‐negative people. The certainty of the evidence was very low for all the outcomes. We downgraded the evidence by two for imprecision, as the CIs for all outcomes range from substantial benefits to clinically important harms. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.

Similar to HIV‐negative people, among people living with HIV, we are also uncertain whether *M. indicus pranii* has an effect on the risk of deaths from all causes ([Analysis 5.1](#CD000526-fig-00501){ref-type="fig"}), deaths from pericarditis ([Analysis 5.2](#CD000526-fig-00502){ref-type="fig"}), constrictive pericarditis ([Analysis 5.3](#CD000526-fig-00503){ref-type="fig"}), repeat pericardiocenthesis ([Analysis 5.4](#CD000526-fig-00504){ref-type="fig"}), cancer ([Analysis 5.5](#CD000526-fig-00505){ref-type="fig"}), hospitalization ([Analysis 5.6](#CD000526-fig-00506){ref-type="fig"}), or opportunistic infections ([Analysis 5.7](#CD000526-fig-00507){ref-type="fig"}) as the current evidence is of very low certainty. There were too few HIV‐positive patients on antiretroviral treatment to assess the effects of *M. indicus pranii* in this group of participants. We downgraded the evidence by two for imprecision, as the CIs for all outcomes range from clinically important benefits to substantial increases in harms. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.

### 5. Open surgical drainage for effusion versus no drainage {#CD000526-sec3-0033}

One trial, conducted in South Africa, assessed the effects of routine open surgical drainage on admission to hospital compared to no intervention among 122 participants with tuberculous pericardial effusion ([@CD000526-bbs2-0007]). This trial started before the onset of the HIV epidemic in South Africa and, although no HIV testing was done, we have assumed the participants to be HIV‐negative.

The results of the trial show that open surgical drainage may reduce the risk of reaccumulation of fluid requiring repeat pericardiocentesis in people without HIV infection (RR 0.23, 95% CI 0.07 to 0.76; [Analysis 6.3](#CD000526-fig-00603){ref-type="fig"}). However, the intervention may make little or no difference to any other outcome measured in the study; including deaths from all causes ([Analysis 6.1](#CD000526-fig-00601){ref-type="fig"}), deaths from pericarditis ([Analysis 6.2](#CD000526-fig-00602){ref-type="fig"}), and pericardiectomy ([Analysis 6.4](#CD000526-fig-00604){ref-type="fig"}). We rated the certainty of the evidence for each of these outcomes as low. We downgraded the evidence by one for imprecision, as the CIs for most outcomes range from clinically important benefits to little or no effect. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.

Discussion {#CD000526-sec1-0006}
==========

Summary of main results {#CD000526-sec2-0011}
-----------------------

This is an update of a Cochrane Review published in 2002 ([@CD000526-bbs2-0065]). Seven randomized controlled trials (RCTs) met the inclusion criteria of this review, and all were conducted in sub‐Saharan Africa. The 2002 review included four trials ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0001]). In addition to updated outcome data from two previously included trials ([@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]), we have included three new trials in this update ([@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]; [@CD000526-bbs2-0002]). Four studies are at low risk of bias ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]), and three are at high risk of bias ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]). The included trials enrolled 1959 participants (54% of them HIV‐positive). Six trials evaluated corticosteroids ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0003]), and one each evaluated colchicine ([@CD000526-bbs2-0002]), *M. indicus pranii* immunotherapy ([@CD000526-bbs2-0003]), and open surgical drainage of pericardial effusion ([@CD000526-bbs2-0007]).

The key findings from these studies are as follows.

In people without HIV infection, corticosteroids probably reduce deaths from pericarditis (*moderate certainty evidence*) and may reduce deaths from all causes and the need for repeat pericardiocentesis (*low certainty evidence*). However, it is uncertain whether corticosteroids have an effect on any other outcome among HIV‐negative people (*very low certainty evidence*) ([Table 1](#CD000526-tbl-0001){ref-type="table"}).In people living with HIV and not on antiretroviral drugs, corticosteroids may reduce constrictive pericarditis and hospitalization (*low certainty evidence*). However, corticosteroids may make little or no difference to the need for repeat pericardiocentesis (*low certainty evidence*) and it is uncertain whether the intervention has an effect on deaths or any other outcome in HIV‐positive people (*very low certainty evidence*) ([Table 2](#CD000526-tbl-0002){ref-type="table"}).It is uncertain whether colchicine has an effect on any outcome among HIV‐positive people (*very low certainty evidence*). All participants were on antiretroviral treatment.It is uncertain whether *M. indicus pranii* has an effect on the risk of deaths or any other outcome, regardless of HIV status (*very low certainty evidence*).In people without HIV infection, routine open surgical drainage for effusion may reduce the need for repeat pericardiocentesis, but may make little or no difference to any other outcome (*low certainty evidence*).

Overall completeness and applicability of evidence {#CD000526-sec2-0012}
--------------------------------------------------

We found that adjunctive corticosteroids may lead to a modest relative reduction of about 20% on the risk of all‐cause mortality among HIV‐negative people. Before the biggest trial on the subject was published ([@CD000526-bbs2-0003]), two small trials, [@CD000526-bbs2-0006] and [@CD000526-bbs2-0007], had previously suggested that adjunctive corticosteroids may reduce mortality by 35% among HIV‐negative patients ([@CD000526-bbs2-0041]). Regarding people living with HIV, currently available data suggest a relative reduction of 9% in mortality, but the CI ranges very widely from a 66% relative reduction to a massive 142% relative increase in mortality. Before the publication of the big trial, [@CD000526-bbs2-0003], data from one small trial suggested that the use of adjunctive corticosteroids among HIV‐positive people with tuberculous pericarditis would result in a 50% relative reduction in mortality ([@CD000526-bbs2-0001]).

Evidence from small early trials on health interventions is often untrustworthy ([@CD000526-bbs2-0062]). An examination of more than 85,000 binary‐outcome forest plots from more than 3000 Cochrane Reviews found that most large treatment effects emerged from small trials and when additional larger trials were performed, the effect sizes typically became much smaller ([@CD000526-bbs2-0048]).

Apart from corticosteroids, we found only one trial each that assessed the effects of colchicine ([@CD000526-bbs2-0002]), *M. indicus pranii* immunotherapy ([@CD000526-bbs2-0003]), and open surgical drainage ([@CD000526-bbs2-0007]).

There is unclear evidence regarding the relationship between corticosteroids, *M. indicus pranii*, and increased rates of cancer. This merits further study. One trial found an association between increased rates of cancer among people randomized to receive both*M. indicus pranii* and corticosteroids ([@CD000526-bbs2-0003]). However, this trial was inadequately powered to determine whether this effect was due to corticosteroids alone, *M. indicus pranii* alone, or a synergistic action between the two interventions.

We aimed to identify the optimal drug combination and treatment duration, but found no eligible trials. This is an important question in the light of the recent demonstration that the concentrations of rifampicin, ethambutol, and pyrazinamide in pericardial fluid based on current treatment regimens were dramatically low and below the minimum inhibitory concentrations of *M. tuberculosis* ([@CD000526-bbs2-0057]). Furthermore, patients with culture‐confirmed tuberculous pericarditis have a high bacillary burden, and this bacterial burden drives mortality ([@CD000526-bbs2-0047]). Therefore the design of a highly bactericidal regimen for this condition is needed, and testing of its effectiveness in RCTs.

Currently there are no RCTs studying the issue of timing of pericardiectomy in people with a diagnosis of tuberculous constrictive pericarditis. The current recommendation of pericardiectomy for persistent signs of constriction after at least six weeks of antituberculous chemotherapy is based on expert opinion ([@CD000526-bbs2-0017]; [@CD000526-bbs2-0040]).

In addition, we found no eligible completed trials that assessed the effects of percutaneous drainage of the pericardium under local anaesthesia, intrapericardial fibrinolysis ([@CD000526-bbs2-0012]), nor novel therapies such as cellular therapy, use of repurposed drugs, and cytokine therapy ([@CD000526-bbs2-0063]).

Quality of the evidence {#CD000526-sec2-0013}
-----------------------

We included seven RCTs in this review. In the GRADE system, RCTs without important limitations constitute high certainty evidence. However, the system considers five factors that can lower the certainty of the evidence: study limitations, heterogeneity, indirectness, imprecision, and publication bias ([@CD000526-bbs2-0013]). Four included studies were well‐conducted RCTs ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]; [@CD000526-bbs2-0003]), at a low overall risk of bias ([Figure 2](#CD000526-fig-0002){ref-type="fig"}; [Figure 3](#CD000526-fig-0003){ref-type="fig"}). Each of the remaining three trials had a high overall risk of bias ([@CD000526-bbs2-0005]; [@CD000526-bbs2-0004]; [@CD000526-bbs2-0002]). These study limitations, as well as the imprecision of most effects, had an important impact on our rating of the certainty of the evidence (see the \'Summary of findings\' tables: [Table 1](#CD000526-tbl-0001){ref-type="table"}; [Table 2](#CD000526-tbl-0002){ref-type="table"}).

Potential biases in the review process {#CD000526-sec2-0014}
--------------------------------------

We minimized potential biases in the review process by adhering to the guidelines of the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD000526-bbs2-0028]). We conducted comprehensive searches of both peer‐reviewed and grey literature, without limiting the searches to a specific language. Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included trial. When a potentially eligible study was conducted by review co‐authors, we requested independent researchers (who were not involved in the article under consideration) to assess eligibility and (if eligible for inclusion) extract data ([@CD000526-bbs2-0030]).

Agreements and disagreements with other studies or reviews {#CD000526-sec2-0015}
----------------------------------------------------------

The previously published version of this Cochrane Review, [@CD000526-bbs2-0065], found that corticosteroids could have important clinical benefits in both HIV‐negative and HIV‐positive people. However, the three included trials were too small to demonstrate a significant effect ([@CD000526-bbs2-0001]; [@CD000526-bbs2-0006]; [@CD000526-bbs2-0007]). The review authors also included one trial that examined open surgical drainage compared with conservative management, and showed that surgery relieved cardiac tamponade ([@CD000526-bbs2-0007]). A year later, Ntsekhe and colleagues published a systematic review of the effectiveness of adjunctive corticosteroids in tuberculous pericarditis, in which they concluded that corticosteroids could have large beneficial effects on mortality and morbidity in tuberculous pericarditis but published trials were too small to be conclusive ([@CD000526-bbs2-0041]). No other systematic review of treatments for tuberculous pericarditis has been published since then.

[@CD000526-bbs2-0029] published a systematic review on the causes, diagnosis, therapy, prevention, and prognosis of pericarditis. However, the authors focused the treatment component of the review on interventions for idiopathic and viral pericarditis in North America and Europe.

This Cochrane Review is therefore the most comprehensive review to date on interventions for treating tuberculous pericarditis.The review\'s findings are slightly different to the largest trial ever completed, authored by some of the authors of this review, which showed no significant difference for corticosteroids on a composite outcome reflecting benefit, and a slight increase in HIV‐associated cancer . The finessing of the results and the interpretation is probably due to multiple factors, including combining with other studies; and re‐analysing the the original trial data stratified by HIV status.

Authors\' conclusions {#CD000526-sec1-0007}
=====================

Our review shows that corticosteroids and open surgical drainage have evidence of benefit in people with tuberculous pericarditis.In HIV‐negative people, corticosteroids probably reduce deaths from pericarditis (*moderate certainty evidence*) and may reduce deaths from all causes (*low certainty evidence*) and the need for repeat pericardiocentesis (*low certainty evidence*); while open surgical drainage may reduce the subsequent need for pericardiocentesis (*low certainty evidence*).In the treatment of people living with HIV not on antiretroviral drugs, corticosteroids may reduce constrictive pericarditis (*low certainty evidence*) and hospitalizations (*low certainty evidence*); with little or no effect on deaths (*low certainty evidence*).The relationship between corticosteroids, immunomodulators, and increased rates of cancer needs to be investigated further. In addition, high‐quality randomized trials are needed on percutaneous drainage of the pericardium under local anaesthesia, the timing of pericardiectomy in tuberculous constrictive pericarditis, new antibiotic regimens, cellular therapy, use of repurposed drugs, and cytokine therapy.We will update this Cochrane Review when the ongoing trial of intrapericardial fibrinolysis is published ([@CD000526-bbs2-0010]).

We thank Paul Garner and David Sinclair for guidance in the preparation of this Cochrane Review.
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**Search setCIDG SR^1^CENTRALMEDLINE^2^Embase^2^ LILACS^2^**1tuberculosisTuberculosis \[MeSH\]Tuberculosis \[MeSH\]Tuberculosis \[MeSH\]tuberculosis2Pericard\*Tuberculosis ti, abTuberculosis ti, abTuberculosis ti, abPericard\*3heart1 or 21 or 21 or 2heart42 or 3heart or cardi\* or pericard\* ti, abheart or cardi\* or pericard\* ti, abheart or cardi\* or pericard\* ti, ab2 or 351 and 43 and 43 and 43 and 41 and 46---\"Pericarditis, Tuberculous\"\[Mesh\]\"Pericarditis, Tuberculous\"\[Mesh\]tuberculous pericarditis \[Emtree\] ---7---5 or 65 or 65 or 6 ---

^1^Cochrane Infectious Diseases Group Specialized Register. ^2^Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration ([@CD000526-bbs2-0033]).

Comparison 1Steroids versus placebo in HIV‐negative peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Deaths from all causes](#CD000526-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 1 Deaths from all causes.4660Risk Ratio (M‐H, Fixed, 95% CI)0.80 \[0.59, 1.09\][2 Deaths from pericarditis](#CD000526-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 2 Deaths from pericarditis.4660Risk Ratio (M‐H, Fixed, 95% CI)0.39 \[0.19, 0.80\][3 Constrictive pericarditis](#CD000526-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 3 Constrictive pericarditis.2281Risk Ratio (M‐H, Fixed, 95% CI)0.72 \[0.34, 1.55\][4 Repeat pericardiocentesis](#CD000526-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 4 Repeat pericardiocentesis.2492Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.70, 1.04\][5 Cancer](#CD000526-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 5 Cancer.1256Odds Ratio (M‐H, Fixed, 95% CI)0.85 \[0.05, 13.80\][6 Hospitalization](#CD000526-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 6 Hospitalization.1256Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.57, 1.70\][7 Pericardiectomy](#CD000526-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 7 Pericardiectomy.4432Risk Ratio (M‐H, Fixed, 95% CI)0.91 \[0.58, 1.41\][8 Opportunistic infections](#CD000526-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Steroids versus placebo in HIV‐negative people, Outcome 8 Opportunistic infections.1256Risk Ratio (M‐H, Fixed, 95% CI)1.71 \[0.44, 6.69\]

Comparison 2Steroids versus placebo in HIV‐positive peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Deaths from all causes](#CD000526-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 1 Deaths from all causes.3575Risk Ratio (M‐H, Random, 95% CI)0.91 \[0.34, 2.42\][2 Deaths from pericarditis](#CD000526-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 2 Deaths from pericarditis.2517Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.46, 2.54\][3 Constrictive pericarditis](#CD000526-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 3 Constrictive pericarditis.3575Risk Ratio (M‐H, Fixed, 95% CI)0.55 \[0.26, 1.16\][4 Repeat pericardiocentesis](#CD000526-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 4 Repeat pericardiocentesis.2517Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.89, 1.18\][5 Cancer](#CD000526-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 5 Cancer.1502Odds Ratio (M‐H, Fixed, 95% CI)1.62 \[0.27, 9.77\][6 Hospitalization](#CD000526-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 6 Hospitalization.1502Risk Ratio (M‐H, Fixed, 95% CI)0.80 \[0.59, 1.09\][7 Pericardiectomy](#CD000526-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 7 Pericardiectomy.115Risk Ratio (M‐H, Fixed, 95% CI)2.1 \[0.10, 44.40\][8 Opportunistic infections](#CD000526-fig-00208){ref-type="fig"}Analysis 2.8Comparison 2 Steroids versus placebo in HIV‐positive people, Outcome 8 Opportunistic infections.2517Risk Ratio (M‐H, Fixed, 95% CI)0.95 \[0.61, 1.48\]

Comparison 3Colchicine versus placebo in HIV‐positive peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Death from all causes](#CD000526-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Colchicine versus placebo in HIV‐positive people, Outcome 1 Death from all causes.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected[2 Constrictive pericarditis](#CD000526-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Colchicine versus placebo in HIV‐positive people, Outcome 2 Constrictive pericarditis.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected

Comparison 4*M. indicus pranii* versus placebo in HIV‐negative peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Deaths from all causes](#CD000526-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 1 Deaths from all causes.1190Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.56, 2.03\][2 Deaths from pericarditis](#CD000526-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 2 Deaths from pericarditis.1190Risk Ratio (M‐H, Fixed, 95% CI)1.5 \[0.44, 5.15\][3 Constrictive pericarditis](#CD000526-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 3 Constrictive pericarditis.1190Risk Ratio (M‐H, Fixed, 95% CI)1.56 \[0.71, 3.42\][4 Repeat pericardiocentesis](#CD000526-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 4 Repeat pericardiocentesis.1190Risk Ratio (M‐H, Fixed, 95% CI)1.21 \[0.96, 1.52\][5 Cancer](#CD000526-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 5 Cancer.1190Odds Ratio (M‐H, Fixed, 95% CI)3.03 \[0.12, 75.37\][6 Hospitalization](#CD000526-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 6 Hospitalization.1190Risk Ratio (M‐H, Fixed, 95% CI)1.22 \[0.70, 2.13\][7 Opportunistic infections](#CD000526-fig-00407){ref-type="fig"}Analysis 4.7Comparison 4 *M. indicus pranii* versus placebo in HIV‐negative people, Outcome 7 Opportunistic infections.1190Risk Ratio (M‐H, Fixed, 95% CI)0.67 \[0.11, 3.90\]

Comparison 5*M. indicus pranii* versus placebo in HIV‐positive peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Deaths from all causes](#CD000526-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 1 Deaths from all causes.1414Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.69, 1.60\][2 Deaths from pericarditis](#CD000526-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 2 Deaths from pericarditis.1414Risk Ratio (M‐H, Fixed, 95% CI)0.51 \[0.16, 1.67\][3 Constrictive pericarditis](#CD000526-fig-00503){ref-type="fig"}Analysis 5.3Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 3 Constrictive pericarditis.1414Risk Ratio (M‐H, Fixed, 95% CI)0.73 \[0.33, 1.60\][4 Repeat pericardiocentesis](#CD000526-fig-00504){ref-type="fig"}Analysis 5.4Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 4 Repeat pericardiocentesis.1414Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.80, 1.10\][5 Cancer](#CD000526-fig-00505){ref-type="fig"}Analysis 5.5Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 5 Cancer.1Odds Ratio (M‐H, Fixed, 95% CI)Totals not selected[6 Hospitalization](#CD000526-fig-00506){ref-type="fig"}Analysis 5.6Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 6 Hospitalization.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected[7 Opportunistic infections](#CD000526-fig-00507){ref-type="fig"}Analysis 5.7Comparison 5 *M. indicus pranii* versus placebo in HIV‐positive people, Outcome 7 Opportunistic infections.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected

Comparison 6Surgical drainage versus no intervention in HIV‐negative peopleOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Death from all causes](#CD000526-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Surgical drainage versus no intervention in HIV‐negative people, Outcome 1 Death from all causes.1122Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.52, 2.20\][2 Death from pericarditis](#CD000526-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Surgical drainage versus no intervention in HIV‐negative people, Outcome 2 Death from pericarditis.1122Risk Ratio (M‐H, Fixed, 95% CI)0.68 \[0.16, 2.91\][3 Repeat pericardiocentesis](#CD000526-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Surgical drainage versus no intervention in HIV‐negative people, Outcome 3 Repeat pericardiocentesis.1122Risk Ratio (M‐H, Fixed, 95% CI)0.23 \[0.07, 0.76\][4 Pericardiectomy](#CD000526-fig-00604){ref-type="fig"}Analysis 6.4Comparison 6 Surgical drainage versus no intervention in HIV‐negative people, Outcome 4 Pericardiectomy.1122Risk Ratio (M‐H, Fixed, 95% CI)0.54 \[0.14, 2.18\]

**DateEventDescription**12 September 2017New citation required and conclusions have changedWe updated this review, added new authors, and included new trials. The conclusion of this review changed compared to the previous published version.12 September 2017New search has been performedThe author team updated this review.

Protocol first published: Issue 4, 1997 Review first published: Issue 3, 1998

**DateEventDescription**10 November 2008AmendedConverted to new review format with minor editing.12 January 2005AmendedNew studies found but not yet included or excluded.18 May 2003AmendedMinor update17 June 2002New citation required and conclusions have changedSubstantive amendment. Issue 4, 2002: Hakim 2000 added.\
New studies found and included or excluded

There are differences between the authors of the protocol and the current version of the review. The protocol had three authors (Bongani Mayosi, Jimmy Volmink, and Patrick Commerford), while this review update has eight review authors.

The protocol set out to assess the effects of only four interventions (six‐month antituberculous drug regimens compared with regimens of nine months or more, corticosteroids, pericardial drainage, and pericardiectomy). However, in this review we have assessed the effects of any intervention used to treat tuberculous pericarditis.

The protocol did not report cancer as a potential outcome, but we have reported outcome data on cancer in this version of the review.

Characteristics of included studies \[ordered by study ID\] {#CD000526-sec2-0019}
===========================================================

[@CD000526-bbs2-0001]MethodsComputer‐generated randomization list\
Double blind placebo controlled trialParticipants58 HIV‐positive participants who were on antituberculous chemotherapy for suspected tuberculous pericarditis.\
Inclusion criteria: (a) age 18 to 55 years; (b) residence in Harare city to ensure good follow up; (c) HIV seropositive; (d) no diagnosis of tuberculosis within the past two years; (e) large pericardial effusion on echocardiography (\> 1 cm anteriorly and \> 1 cm posteriorly; and (f) pericardial aspirate with \> 50% lymphocytes and protein content \> 30 g/L.\
Exclusion criteria: (a) antituberculous treatment started more than 48 hours before recruitment; (b) corticosteroid treatment within previous one month; (c) presence of Kaposi's sarcoma or any other malignancy; (d) coexisting life threatening disease; (e) bacterial pneumonia; (f) pregnancy; (g) cavitating pulmonary tuberculosis; and (h) other causes of pericardial effusion.\
\"All patients received a standard short course anti tuberculous regimen in accordance with national guidelines. This included rifampicin, isoniazid, pyrazinamide, and ethambutol for two months, followed by rifampicin and isoniazid for a further four months in standard doses.\"Interventions**Intervention**\
Prednisolone for the first 6 weeks of antituberculous chemotherapy.Dose for adults: 60 mg for the first week, and tapering by 10 mg every week.\
**Control**\
Placebo.Outcomes**Primary outcomes**\
Death.Resolution of pericardial effusion.\
**Secondary outcomes**\
Resolution of pretreatment symptoms and signs, and ECG changes.Corticosteroid‐related adverse effects.NotesStudy location: Harare, Zimbabwe***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Randomisation was achieved by the use of a computer generated randomisation list\".Allocation concealment (selection bias)Low risk\"Prednisolone/placebo packages were prepared according to the randomisation list, but labelled with the study number only. A package consisted of six well labelled bottles each containing the number of tablets required in each of the six weeks of the intervention. Eligible patients were given a drug package consecutively working down the randomisation list.\"Blinding of participants and personnel (performance bias) All outcomesLow risk\"Clinicians and patients were blinded to the identity of the tablets. A randomisation code list was kept sealed and was released at the end of the study\".Blinding of outcome assessment (detection bias) All outcomesLow riskTwo cardiologists with extensive experience of echocardiography in this setting performed all examinations. \"Clinicians and patients were blinded to the identity of the tablets. A randomisation code list was kept sealed and was released at the end of the study\".Incomplete outcome data (attrition bias) All outcomesLow riskFollow‐up data was available on all 58 enrolled participants.Selective reporting (reporting bias)Unclear riskThe study protocol was not available and there is no earlier methods paper listing the prespecified outcomes.Other biasLow riskThere is no evidence that the study had any additional biases to the ones mentioned above.[@CD000526-bbs2-0002]MethodsParticipants \"were randomised to an intervention and control group using a web‐based computer system that ensured assignment concealment\".\
\"Upon completion of the research period, the blinding was unveiled and data were presented for statistical analysis\".Participants33 HIV‐positive people with definite or probable tuberculous pericarditis at a secondary level hospital in the Northern Cape of South Africa.\
All participants received standard treatment according to the South African National Tuberculosis Management Guidelines, that is weight‐adjusted antituberculosis drugs and oral corticosteroids for 4 weeks. Participants also had pericardial \"aspiration until dryness\", and antiretroviral therapy.Interventions**Intervention**\
Colchicine 1.0 mg per day for 6 weeks.\
**Comparison**\
Placebo for 6 weeks.\
Participants were followed up with serial echocardiography for 16 weeks.Outcomes**Primary outcome**\
Constrictive pericarditis.NotesStudy location: Kimberley, South Africa.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe mention of an internet‐based computer system implies use of a computer‐generated randomization sequence.Allocation concealment (selection bias)Low riskParticipants \"were randomised to an intervention and control group using a web‐based computer system that ensured assignment concealment\".Blinding of participants and personnel (performance bias) All outcomesUnclear riskThe study authors reported that \"Upon completion of the research period, the blinding was unveiled and data were presented for statistical analysis\", but did not provide further details of blinding.Blinding of outcome assessment (detection bias) All outcomesLow riskThe study reported that blinding was unveiled only after completion of the follow‐up period, when presenting data to the statistician.Incomplete outcome data (attrition bias) All outcomesHigh riskIn this study, 5/33 (15.15%) participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskWe do not have access to the study protocol and are unable to comment on whether there was selective reporting of outcomes in this study.Other biasLow riskThere was no evidence of other sources of bias in the study.[@CD000526-bbs2-0003]MethodsComputer‐generated randomization list\
Double‐blind placebo‐controlled 2 × 2 factorial studyParticipants1400 participants (two‐thirds HIV‐positive) 18 years of age or older, with a pericardial effusion confirmed by echocardiography, evidence of definite or probable tuberculous pericarditis, and had begun antituberculous treatment less than 1 week before enrolment.\
"Trial participants received antimicrobial treatment for tuberculosis and antiretroviral treatment for HIV according to World Health Organization (WHO) guidelines; management during the course of the trial was revised as recommended treatment practices evolved".Interventions**Intervention 1**\
Prednisolone for 6 weeks at a dose of 120 mg per day in the first week, 90 mg per day in the second week, 60 mg per day in the 3rd week, 30 mg per day in the 4th week, 15 mg per day in the 5th week, and 5 mg per day in the 6th week.\
**Control 1**\
Identical placebo for 6 weeks at a dose of 120 mg per day in the 1st week, 90 mg per day in the 2nd week, 60 mg per day in the 3rd week, 30 mg per day in the 4th week, 15 mg per day in the 5th week, and 5 mg per day in the 6th week.\
**Intervention 2**\
*M. indicus pranii* preparation (CADI‐Mw injection, Cadila Pharmaceuticals) in 5 doses: at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The 1st dose was given as 2 injections of 0.1 mL (containing 0.5 × 10^9^ organisms) in each deltoid region of the upper arm; the 4 subsequent doses were given as a single injection of 0.1 mL.\
**Control 2**\
Identical placebo in 5 doses: at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The 1st dose was given as 2 injections of 0.1 mL in each deltoid region of the upper arm; the 4 subsequent doses were given as a single injection of 0.1 mL.Outcomes**Primary outcome**\
Composite of death or 1st occurrence of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.\
**Secondary outcomes**\
Individual components of the primary outcome.Hospitalization.\
**Safety outcomes**\
Opportunistic infections.Cancer.CD4+ T‐lymphocyte cell count (measure of immunosuppression) and immune reconstitution inflammatory syndrome (in HIV‐positive).NotesStudy location: multiple sites in South Africa, Mozambique, Malawi, Uganda, Sierra Leone, Zimbabwe, Kenya, and Nigeria***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated randomization list.Allocation concealment (selection bias)Low riskCentral allocation, stratified by centre, with random block sizes.Blinding of participants and personnel (performance bias) All outcomesLow riskBoth prednisolone and *M. indicus pranii* preparation had identical placebos.Blinding of outcome assessment (detection bias) All outcomesLow riskA committee of clinicians blinded to treatment allocation (the Outcomes Adjudication Committee) adjudicated all primary and secondary outcomes.Incomplete outcome data (attrition bias) All outcomesLow riskParticipants were analysed in groups to which they were randomized, regardless of how much of the intended intervention they actually received. Primary outcome data were known for 1371 of 1400 (97.9%) participants in the prednisolone‐placebo comparison; with no significant differences between prednisolone (688/706;. 97.5%) and placebo (683/694; 98.4%) arms. For the *M. indicus pranii* ‐ placebo comparison, primary outcome data were available for 1223 of 1250 participants (97.8%); with no significant differences between *M. indicus pranii* (611/625; 97.8%) and placebo (612/625; 97.9%).Selective reporting (reporting bias)Low riskThe study authors reported the outcomes planned for in the prospective trial registration (ClinicalTrials.gov registration number NCT100810849) and published protocol in the trial report.Other biasLow riskThere was no evidence of other biases in the study.[@CD000526-bbs2-0004]MethodsComputer‐generated randomization list\
Double‐blind placebo‐controlled studyParticipants57 participants, aged 17 to 66 years, with large pericardial effusions on echocardiography, pericardial aspirate with protein content \> 30 g/L, and pericardial fluid adenosine deaminase (ADA) activity \> 35 U/L; 23 females and 34 males; 40 had microbiological or histological evidence of TB or both, and 17 patients were diagnosed by clinical and supportive laboratory data. 21 (37.0%) were HIV‐positive.\
\"A standard short‐course anti‐tuberculous regimen was initiated according to national guidelines, namely a combination of rifampicin, isoniazid, pyrazinamide and ethambutol for two months, followed by rifampicin and isoniazid for a further four months\...Patients were discharged on anti‐tuberculous therapy and pyridoxine, with or without adjunctive prednisone. HIV‐positive patients also received daily oral cotrimoxazole; due to the prevailing national policy at the time of this study, none of these patients received antiretroviral therapy\".Interventions**Intervention 1**\
200 mg (5 mL) intrapericardial triamcinolone hexacetonide. Triamcinolone was injected directly into the pericardium just prior to the removal of the indwelling catheter. Due to limited resources, an oral placebo was not used in conjunction with the intrapericardial triamcinolone. 17 participants were in this arm, 6 (35%) were HIV‐positive.\
**Intervention 2**\
Oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution). Oral prednisone was started at 60 mg/day for 4 weeks, followed by 30 mg/day for 4 weeks, 15 mg/day for 2 weeks and 5 mg/day for 1 week. There were 16 participants in this arm, 9 (56%) were HIV‐positive.\
**Control**\
Placebo (5 mL intrapericardial 0.9% saline). 24 participants were included in this arm, and 6 (25%) were HIV‐positive.Outcomes**Primary outcome**\
All‐cause mortality.\
**Secondary outcomes**\
Death attributed to pericarditis.Disability related to pericardial disease at 1 year (defined as a history of restricted physical activity using New York Heart Association functional classification.Effusive constriction.Fibrous constrictive pericarditis requiring pericardiectomy.NotesStudy location: Cape Town, South Africa.\
We excluded data from the intrapericardial triamcinolone arm from this review.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskParticipants were \"randomly assigned as per a predetermined randomisation schedule for 100 patients on a 3:3:4 basis. Numbers were drawn from a hat, stored on a list on a computer and provided to the treating physician with the assigned treatment by a non‐clinical administrator.\"Allocation concealment (selection bias)High riskAn unblinded, independent physician administered one of the three randomly assigned treatment options.Blinding of participants and personnel (performance bias) All outcomesLow risk\"The randomisation code remained concealed and was not revealed to the investigators or the study subjects until completion of the study.\"Blinding of outcome assessment (detection bias) All outcomesUnclear riskThe study states that outcomes were assessed using a combination of clinical and echocardiographic features, but there is no mention of blinding of outcome assessment.Incomplete outcome data (attrition bias) All outcomesHigh riskNine (16.0%) participants were lost to follow‐up.Selective reporting (reporting bias)Unclear riskWe do not have access to the study protocol and are unable to comment on whether there was selective reporting of outcomes in this study.Other biasLow riskNo evidence of other biases[@CD000526-bbs2-0005]MethodsAlternate allocation of 28 participants to adjuvant steroids or no steroidsParticipants28 participants who were on antituberculous chemotherapy for suspected tuberculous pericarditis. The trial authors did not provide the characteristics of the included participants, and did not specify the antituberculous drugs used.Interventions**Intervention**\
Cortisone with a loading dose of 300 mg and maintenance dose of 100 mg daily for several weeks was prescribed for 14 participants. At a later date, prednisolone 60 mg/day with a maintenance dose of 20 mg was substituted.\
**Control**\
No corticosteroids.\
The trial authors did not specify the length of follow‐up.OutcomesConstriction requiring pericardiectomyNotesStudy location: Cape Town, South Africa***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskThe trial authors performed randomization by alternation.Allocation concealment (selection bias)High riskThere was no allocation concealment.Blinding of participants and personnel (performance bias) All outcomesHigh riskThe trial did not perform any blinding.Blinding of outcome assessment (detection bias) All outcomesHigh riskThere was no evidence of blinding of outcome assessors.Incomplete outcome data (attrition bias) All outcomesUnclear riskThe trial authors did not adequately report losses to follow‐up.Selective reporting (reporting bias)Unclear riskThe study protocol was not available.Other biasLow riskThere was no evidence of other sources of bias.[@CD000526-bbs2-0006]MethodsCentral randomization\
Double blind placebo‐controlled studyParticipants143 participants with suspected tuberculous constrictive pericarditis aged 5 years and older. The participants in the treatment and control groups were well‐matched in terms of clinical characteristics and completion of antituberculous chemotherapy.\
\"Those consenting to take part were all prescribed the same 6‐month standard antituberculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14 weeks as an in‐patient, followed by isoniazid and rifampicin daily up to 6 months.\"Interventions**Intervention**\
Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.\
**Control**\
Matching placebo.OutcomesDeath.Death from pericarditis.Favourable clinical status at 24 months.Pericardiectomy.NotesStudy location: Umtata, South Africa***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used a random number list.Allocation concealment (selection bias)Low riskThe trial authors used central randomization.Blinding of participants and personnel (performance bias) All outcomesLow riskParticianpts and care providers were blinded to treatment.Blinding of outcome assessment (detection bias) All outcomesLow riskInvestigators, including outcome assessors, were blinded to treatment allocation.Incomplete outcome data (attrition bias) All outcomesLow riskDuring 10 years of follow‐up, 1 participant (1.4%) was lost to follow‐up in the prednisolone group and 2 participants (2.7%) in the placebo group.Selective reporting (reporting bias)Unclear riskThere was no study protocol available.Other biasLow riskThere was no evidence of other sources of bias.[@CD000526-bbs2-0007]MethodsCentral randomization\
Double blind placebo‐controlled study\
Factorial designParticipants240 participants aged 5 years or more diagnosed as having active tuberculous pericardial effusion. The participants in the treatment and control groups were well‐matched in terms of their clinical characteristics and completion of antituberculous chemotherapy.\
\"Those consenting to take part were all prescribed the same 6‐month standard antituberculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14 weeks as an in‐patient, followed by isoniazid and rifampicin daily up to 6 months.\"Interventions**Intervention 1**\
Complete open surgical drainage on admission.\
**Control 1**\
No open drainage.\
**Intervention 2**\
Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.\
**Control 2**\
Matching placebo.OutcomesDeath.Death from pericarditis.Favourable clinical status at 24 months.Tamponade requiring pericardiocentesis.Constriction.Pericardiectomy.NotesStudy location: Umtata, South Africa***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a random number list to perform random sequence generation.Allocation concealment (selection bias)Low riskThe trial authors performed central randomization.Blinding of participants and personnel (performance bias) All outcomesLow riskThe participants and investigators were blinded to the steroid component, but not to the surgical drainage component.Blinding of outcome assessment (detection bias) All outcomesLow risk\"For patients who died, information was obtained on cause of death from hospital records, relatives, or other contacts. All the deaths were reviewed by an independent assessor without knowledge of the treatment group, and where possible, he classified the cause.\"Incomplete outcome data (attrition bias) All outcomesLow risk5/117 (4.3%) participants were lost to follow‐up in the prednisolone group compared to 7/119 (5.9%) in the placebo group.\
2/64 (3.1%) participants were lost to follow‐up in the drainage group compared to 3/58 (5.2%) in the no drainage group.Selective reporting (reporting bias)Unclear riskThere was no study protocol available.Other biasLow riskThere was no evidence of other sources of bias.

Characteristics of excluded studies \[ordered by study ID\] {#CD000526-sec2-0020}
===========================================================

StudyReason for exclusion[@CD000526-bbs2-0008]Although this study is indexed in electronic databases as a controlled trial, it is actually a cross‐sectional study of the contemporary use of adjunctive steroids by physicians treating patients with tuberculous pericarditis. We thus excluded it from this review due to ineligible study design.

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD000526-sec2-0021}
======================================================================

[@CD000526-bbs2-0009]MethodsConsecutively recruited participants were \"randomly\" assigned to intervention or control arms, but no further details about random sequence generation and allocation concealment are not provided in the abstract. The length of following‐up varied from 8 to 120 months (mean 56.8 ± 29.0 months).ParticipantsNinety‐four participants with infectious exudative pericarditis (34 with purulent pericarditis and 60 with tuberculous pericarditis); disease course less than 1 month; 44 males and 50 females; age 9 to 66 years (mean 45.4 ± 14.7 years); consecutively enrolled between 1993 to 2002 in China. The hospital and city are not specified.InterventionsIntervention arm: intrapericardial urokinase along with conventional treatment in intervention arm, or conventional treatment alone (including pericardiocentesis and drainage) in the control arm. The dosage of urokinase ranged from 200,000 to 600,000 U (mean 320,000 ± 70,000 U).OutcomesPericardial constriction, as detected by pericardiography with sterilized air and diatrizoate meglumine as contrast media (in the short‐tem) and telephonic survey and echocardiographic examination (in the long‐term).NotesStudy published in Chinese. Only the abstract is currently available in English.

Characteristics of ongoing studies \[ordered by study ID\] {#CD000526-sec2-0022}
==========================================================

[@CD000526-bbs2-0010]Trial name or titleThe Second Investigation of the Management of Pericarditis (IMPI‐2) TrialMethods**Study design**: randomized trial\
**Intervention model**: parallel assignment\
**Blinding**: single blind (outcomes assessor)ParticipantsThe study plans to enrol 2176 participants.\
**Inclusion criteria**\
Age ≥ 18 years of age.Confirmed large pericardial effusion on echocardiography (that is, echo free space ≥ 1 cm anterior to the right ventricle of the heart in diastole).Willingness to participate for the full duration of the trial (that is, 12 months).Provision of written informed consent.\
**Exclusion criteria**\
Age \< 18 years.Uraemic pericarditis (that is, urea \> 21.4 mmol/L).Thrombocytopenia (that is, \< 100,000 platelets/µL).Presence of a contraindication to the administration of a fibrinolytic agent (major haemorrhage or major trauma; coincidental stroke; major surgery in the previous 5 days; blood pressure \> 200/100 mmHg).Interventions**Intervention**: complete percutaneous pericardial drainage facilitated by intrapericardial alteplase (recombinant human tissue‐type plasminogen activator).\
**Comparison**: conventional pericardiocentesis.Outcomes**Primary outcomes**\
Composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.\
**Secondary outcomes**\
Major bleeding.Clinically relevant non‐major bleeding.Any bleeding.Any other form of bleeding that is not covered by safety outcomes 1‐3.Other adverse events.Any other adverse events.Persistent pericardial effusion without cardiac tamponade.Recurrent pericardial effusion without cardiac tamponade.Hospitalization for any cause; and death from any cause.Cardiac tamponade requiring pericardiocentesis.Constrictive pericarditis.Death from any cause.Proportion with proven tuberculosis.Time to diagnosis of proven tuberculosis.Proportion with proven tuberculosis on novel tests who are not put on treatment.Diagnostic accuracy of novel tests of tuberculosis.Drug‐resistant tuberculosis.Specific diagnosis of tuberculous pericarditis.Time to diagnosis of specific pericardial disease.Starting dateThe study started in February 2016, with the planned completion date as January 2019.Contact information**Principal investigator**: Professor Bongani M, Mayosi, University of Cape Town, Cape Town, South Africa.\
**Contacts:**\
Shaheen Pandie: Phone +27823199030; Email: [s.pandie\@uct.ac.za](s.pandie@uct.ac.za)Veronica Francis: Phone +27832449895; Email: [veronica.francis\@uct.ac.za](veronica.francis@uct.ac.za)Notes**Sponsor:** University of Cape Town, South Africa.\
**Collaborators:** Walter Sisulu University, South Africa; Population Health Research Institute, Canada

Charles S Wiysonge and Bongani M Mayosi led the preparation of the current version of the review, with important intellectual inputs from all co‐authors. Charles S Wiysonge and Bongani M Mayosi were involved in all stages of the review. Dumisani Majombozi was involved in screening of searches, study selection, data extraction, and verification of data analysis. Freedom Gumedze provided the data on the [@CD000526-bbs2-0003] trial and verified the data analysis. Mpiko Ntsekhe, Lehana Thabane, Jimmy Volmink, and Shaheen Pandie read and provided important input into successive drafts of the review. All review authors read and approved the final version of the review.
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Cardiac Clinic Research Fund, University of Cape Town, South Africa.Stellenbosch University, South Africa.South African Medical Research Council, South Africa.Liverpool School of Tropical Medicine, UK.

External sources {#CD000526-sec2-0018}
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Department for International Development, UK.Grant: 5242

Mpiko Ntsekhe, Lehana Thabane, Freedom Gumedze, Shaheen Pandie, and Bongani M Mayosi were investigators in an included study ([@CD000526-bbs2-0003]). Jimmy Volmink was a member of the Data Safety and Monitoring Committee for the same study. However, two review authors (CSW and DM) who were not involved in this trial independently extracted the data for this study, which were verified by Paul Garner, David Sinclair, Hannah Ryan, and Maya Tickell‐Painter.

Charles S Wiysonge, Mpiko Ntsekhe, Jimmy Volmink, and Bongani M Mayosi were co‐authors of a study assessed and excluded from the review ([@CD000526-bbs2-0008]). A review author (DM) who was not involved in this study initially assessed the eligibility of this study.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^We downgraded by 1 for imprecision: the CI ranges from a large clinical benefit to a small increase in harm. ^2^We downgraded by 1 for study limitations: one trial was at high risk of bias. ^3^We downgraded by 2 for imprecision: the CI ranges from clinically important benefits to a large increase in harm. ^4^We downgraded by 1 for selective reporting: data were only reported by 2 of the 4 trials that recruited HIV‐negative people. ^5^We downgraded by 1 for selective reporting: data were only reported by 1 of the 4 trials that recruited HIV‐negative people.

[^3]: ^1^We downgraded by 2 for imprecision: the CI ranges from substantial clinical benefits to substantial harm. ^2^We downgraded by 1 for unexplained heterogeneity (Chi² = 3.82, df = 1 (P = 0.05); I² statistic = 74%). ^3^We downgraded by 1 for selective reporting: only 2 of the 3 studies that recruited HIV‐positive people reported data. ^4^We downgraded by 1 for study limitations: 1 study had a high risk of bias. ^5^We downgraded by 1 for imprecision: the CI ranges from a small beneficial effect to clinically important harms.

[^4]: Abbreviations: ART: proportion of participants on antiretroviral therapy; HIV: human immunodeficiency virus; TB: tuberculosis.

    ^1^In the [@CD000526-bbs2-0005] study, corticosteroid dose was given at a loading dose of 300 mg daily followed by a maintenance dose of 100 mg daily. At a later date, cortisone was substituted by prednisolone with a loading dose of 60 mg daily and a maintenance dose of 20 mg daily. ^2^In the [@CD000526-bbs2-0006] and [@CD000526-bbs2-0007] , the trial authors stratified prednisolone dosing by age: The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. For children 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 11. ^3^In the [@CD000526-bbs2-0001] study, the dose of prednisolone was 60 mg daily for the first week and was tapered thereafter by 10 mg every week. ^4^In the [@CD000526-bbs2-0004] study, the corticosteroid arm received oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution). Oral prednisone was started at 60 mg per day for 4 weeks, followed by 30 mg per day for 4 weeks, 15 mg per day for 2 weeks, and 5 mg per day for 1 week. This study had 3 arms. We did not include the third trial arm, which received intrapericardial triamcinolone, in this current review. ^5^[@CD000526-bbs2-0003] used prednisolone for six weeks at a dose of 120 mg per day in the first week, 90 mg per day in the second week, 60 mg per day in the third week, 30 mg per day in the fourth week, 15 mg per day in the fifth week, and 5 mg per day in the sixth week.
